Dexmedetomidine: Clinical Application as an Adjunct for Intravenous Regional Anesthesia

Optimizing pain management to facilitate Enhanced Recovery After Surgery pathways

“…74 The addition of dexmedetomidine to intravenous regional anesthetic solutions prolongs analgesia and motor blockade. 75 Additionally, an intravenous dexmedetomidine infusion (0.2-0.8 lgÁkg -1 Áhr -1 ) before wound closure was shown to decrease PACU opioid requirements, PACU stay, and PONV after laparoscopic bariatric surgery. Capsaicin is a non-narcotic agent with agonist activity at peripheral TRPV1 receptors.…”

Dexmedetomidine renders a brain protection on hippocampal formation through inhibition of nNOS-NO signalling in endotoxin-induced shock rats

“…It is relatively unusual in its ability to provide sedation without causing respiratory depression. Like clonidine, it is an agonist of 2 -adrenergic receptors in certain parts of the brain [13]. It is found that dexmedetomidine dose-dependently attenuates extremely high mortality rates and increases in plasma cytokine concentrations after endotoxin injection and reduce NO level in hippocampal tissue to decrease neuron apoptosis in ischaemia-reperfusion brain injury of rats [14][15][16][17].…”

The Efficacy of Adding Lornoxicam-Dexmedetomidine to 0.25% Diluted Lidocaine for Intravenous Regional Anesthesia

“…Iclal O et al [20] added either dexmedetomidine or lornoxicam to IRA for upper limb surgeries and found that both of them provided good analgesic and anaesthetic quality without causing adverse effects as no hypotension, bradycardia or hypoxia requiring treatment was seen in any of the patients. Also Ramadhyani U et al [21] proved that the addition of dexmedetomidine to IVRA solutions improved postoperative analgesia as well as decreased the total local anesthetic dose.…”